北京智源鸿晟生物医药

Beijing Zhiyuan Hongsheng Biological Medicine is a Chinese biotechnology company focused on the development of innovative immune cell therapies for cancer treatment. The company leverages its proprietary technology platforms to engineer CAR-T and TCR-T cells targeting both hematological malignancies and solid tumors. Zhiyuan Hongsheng aims to address unmet medical needs through advanced cell engineering and clinical translation. Their research emphasizes improving the efficacy and safety of cell-based immunotherapies in complex tumor microenvironments. The company is led by Dr. Zhang Hongsheng, a recognized expert in the field of CAR-T cell research who has been instrumental in advancing cell therapy in China.